Which treatment is listed for sinus bradycardia?

Which treatment is listed for sinus bradycardia?

• A. Atropine
• B. Oxygen
• C. Amiodarone
• D. Lidocaine

Answer: (A)

Sinus bradycardia is when the sinus node fires too slowly, and the goal in a symptomatic patient is to speed up the heart rate. The best first-line pharmacologic treatment is atropine, an anticholinergic that blocks the vagal (parasympathetic) effect on the SA and AV nodes. By reducing acetylcholine’s influence, atropine increases automaticity and improves conduction, producing a faster heart rate. It works quickly when given IV, which is why it’s the go-to in acute management of symptomatic bradycardia. Oxygen is important if hypoxemia or respiratory distress is present, but it doesn’t directly address the slowed rate. Amiodarone and lidocaine are antiarrhythmics used mainly for tachyarrhythmias or ventricular rhythms, not for treating a slow heart rate, so they aren’t appropriate choices for sinus bradycardia. If atropine doesn’t work, other steps like pacing or vasoactive infusions may be needed, but atropine remains the initial targeted treatment for this scenario.

Sinus bradycardia is when the sinus node fires too slowly, and the goal in a symptomatic patient is to speed up the heart rate. The best first-line pharmacologic treatment is atropine, an anticholinergic that blocks the vagal (parasympathetic) effect on the SA and AV nodes. By reducing acetylcholine’s influence, atropine increases automaticity and improves conduction, producing a faster heart rate. It works quickly when given IV, which is why it’s the go-to in acute management of symptomatic bradycardia.

Oxygen is important if hypoxemia or respiratory distress is present, but it doesn’t directly address the slowed rate. Amiodarone and lidocaine are antiarrhythmics used mainly for tachyarrhythmias or ventricular rhythms, not for treating a slow heart rate, so they aren’t appropriate choices for sinus bradycardia. If atropine doesn’t work, other steps like pacing or vasoactive infusions may be needed, but atropine remains the initial targeted treatment for this scenario.